{
    "2021-05-24": [
        [
            {
                "time": "2023-10-01",
                "original_text": "Big Drug Stocks Have Rallied. Why an Analyst Says They Have More Room to Run.",
                "features": {
                    "keywords": [
                        "Drug Stocks",
                        "Rallied",
                        "Analyst",
                        "More Room"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "10 Best Dividend Stocks to Buy According to Billionaire Mario Gabelli",
                "features": {
                    "keywords": [
                        "Dividend Stocks",
                        "Buy",
                        "Billionaire",
                        "Mario Gabelli"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "dividends"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "AbbVie Presents New Late-Breaking Data Analyses Showing Risankizumab (SKYRIZI®) Achieves Clinical Remission and Endoscopic Response at Week 12 in Patients with Moderate to Severe Crohn's Disease",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Risankizumab",
                        "SKYRIZI",
                        "Clinical Remission",
                        "Crohn's Disease"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "The Lancet Publishes Results from Pivotal Global Phase 3 Program Evaluating RINVOQ® (upadacitinib) in Atopic Dermatitis",
                "features": {
                    "keywords": [
                        "The Lancet",
                        "RINVOQ",
                        "Phase 3",
                        "Atopic Dermatitis"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "JNJ's Stelara Fails to Beat AbbVie's Humira In Crohn's Disease Patients",
                "features": {
                    "keywords": [
                        "JNJ",
                        "Stelara",
                        "AbbVie",
                        "Humira",
                        "Crohn's Disease"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}